GUSA Analysts See 19% Upside Despite Current Trading Price

GUSA analysts foresee 19.07% upside in the ETF, with significant targets for holdings BBIO, MOG.A, and KVYO. Future performance may hinge on analyst optimism and market conditions.

Date: 05-03-2025

AI Rating: 7

Investor Analysis Report

In reviewing the report, it is clear that the Goldman Sachs MarketBeta US 1000 Equity ETF (GUSA) is showing a promising upside potential. Analysts have set an average 12-month target price for GUSA at $59.52, indicating a potential upside of 19.07% from its recent trading price of $49.99. This signals that the ETF may be undervalued currently.

Moreover, examining GUSA's underlying holdings reveals significant upside as well:

BridgeBio Pharma Inc (BBIO) has a notable 58.62% upside potential. The recent trading price is at $33.54, while the average target is $53.20.
Moog Inc (MOG.A) portrays a 40.45% upside, trading at $162.33 against an average target of $228.00.
Klaviyo Inc (KVYO) shows a 36.42% upside potential, with a recent price of $37.73 and a target price of $51.47.

This bullish outlook from analysts could reflect growing confidence in the market or underlying factors that could drive future growth for these companies. Nonetheless, the report raises speculation about the justification behind these target prices; while they may harbor optimistic views on the future, they could also risk target price downgrades should the predictions not materialize.

Stocks: GUSA BBIO MOG.A KVYO